



REGIONAL PEDIATRIC PARENTERAL DRUG MONOGRAPH

GENERIC NAME

amiodarone



Effective Date: Dec 2011	CLASSIFICATION Antiarrhythmic	OTHER NAMES Cordarone	PAGE 1 of 2
Revised Date: Dec 2022			

ADMINISTRATION POLICY:

- IV Infusion – Administration restricted to nurses experienced in ED/CARDIAC ROOM/ICU/PACU
- IV Intermittent- Administration restricted to nurses experienced in ED/CARDIAC ROOM/ICU/PACU
- IV Bolus – Administration restricted to nurses experienced in ED/CARDIAC ROOM/ICU/PACU

RECONSTITUTION/DILUTION/ADMINISTRATION:

Available as: 50 mg/mL – 3 mL ampoule

IV Bolus: Administer undiluted (no filter required) over 1 to 2 minutes

IV Intermittent: Infuse over 20 to 60 minutes

IN-LINE 0.22 MICRON FILTER REQUIRED

IV Infusion: Pump Library: Must be diluted in non-PVC bag (ie: Excel). PVC tubing must be used.

Drug Library	Dose Rate	Short Name	Care Unit
Yes	mcg/kg/min	amio450	Pediatric
Drug	Diluent	Final Volume (VTBI)	Final Concentration
450 mg (9 mL of 50 mg/mL)	250 mL of D5W	259 mL	1.737 mg/mL
Clinical Advisory: High Alert			
Soft Low Dose Limit: 5 mcg/kg/ min		Soft High Dose Limit: 15 mcg/kg/ min	

DOSAGE:

IV Bolus: 5 mg/kg during cardiac arrest. May repeat up to two times for refractory ventricular fibrillation/pulseless ventricular tachycardia up to a maximum total dose of 15 mg/kg during acute treatment.

Load: IV Intermittent: 5 mg/kg, may repeat initial load to a maximum total initial load of 10 mg/kg do not exceed total daily bolus of 15 mg/kg/day

Maintenance: IV infusion: 5 to 15 mcg/kg/minute, titrated to response (maximum daily dose: 2200 mg/day)

Maximum single dose: IV Bolus/ Intermittent: 300 mg/ dose

Maximum rate: Intermittent: over 20 minutes

Infusion: 15 mcg/kg/minute

Maximum concentration: Intermittent/Infusion: Peripheral: 2.5 mg/mL

Central: 6mg/mL



REGIONAL PEDIATRIC PARENTERAL DRUG MONOGRAPH

GENERIC NAME

amiodarone



Effective Date: Dec 2011	CLASSIFICATION Antiarrhythmic	OTHER NAMES Cordarone	PAGE 2 of 2
Revised Date: Dec 2022			
STABILITY/COMPATIBILITY: Stability of open vial: Discard unused portion immediately Stability of Final Admixture: Non-PVC (polyolefin, glass, syringe, Excel bag): 24 hours at room temperature Compatibility: Compatible with D5W, normal saline			
PRECAUTIONS, POTENTIAL ADVERSE REACTIONS: <ul style="list-style-type: none"> • CV: Hypotension, bradycardia, cardiac arrest • Hepatic: Increase in liver enzymes • Local: Phlebitis at infusion site (reduced with in-line filter) • Resp: Pulmonary inflammation, fibrosis (long-term) • Other: Alopecia, corneal deposits, photosensitivity/skin discoloration, hypo/hyperthyroidism • Concurrent use of narcotic, benzodiazepines or agents with hypotensive effects may produce significant hypotension and/or bradyarrhythmia • Contraindicated with hypersensitivity to iodine • Contraindicated with cardiogenic shock, severe sinus node dysfunction, marked sinus bradycardia second or third degree AV block, acute hepatitis, pre-existing thyroid dysfunction, pulmonary interstitial abnormalities 			
ADDITIONAL NOTES AND NURSING CONSIDERATIONS: <ul style="list-style-type: none"> • Required monitoring <ul style="list-style-type: none"> ○ Continuous cardiac monitoring during administration ○ Blood pressure 			